If you have been reading about mass spectrometry and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-05-05. Where a claim depends on a specific study, the study is described rather than over-claimed.
Semax is normally supplied as a lyophilized powder, and that form is the most stable. Suppliers commonly recommend storage at -20 °C in a desiccated container protected from light, with short-term handling at room temperature limited to weighing and transfer. Powder that has absorbed moisture degrades faster, so vials should be warmed to ambient temperature before opening to prevent condensation on the contents. Hygroscopic behavior is typical of short hydrophilic peptides, and humidity control matters more than temperature alone for long-term retention.
Once dissolved, the peptide is considerably less stable than the solid. Aqueous solutions are usually prepared at neutral to slightly acidic pH, filtered, and divided into single-use aliquots before freezing. Repeated freeze-thaw cycles are a common cause of avoidable loss and are best prevented by never refreezing a thawed aliquot. Adsorption to plastic and glass surfaces can lower the measured concentration of dilute solutions, particularly below roughly 0.1 mg/mL. Buffer choice, salt content, and container material all influence how much peptide remains detectable after storage.
Identity and purity of semax are established with reversed-phase high-performance liquid chromatography coupled to ultraviolet detection, usually at 214 nanometres. Mass spectrometry, most often electrospray ionisation in positive mode, confirms the molecular mass and reveals truncated sequences. Amino acid analysis and peptide mapping after enzymatic digestion provide additional structural confirmation. Laboratories typically report purity as the percentage area of the main peak, a figure that does not capture isomeric or oxidised variants unless the method resolves them.
The peptide is prone to several degradation pathways. Oxidation of the methionine residue produces a sulfoxide that elutes close to the parent peak in many chromatographic systems. Hydrolysis of peptide bonds and deamidation of susceptible residues in related sequences also reduce purity over time. Lyophilised material kept dry at minus twenty degrees Celsius and shielded from light is the most stable form commonly described in laboratory practice.
| Property | Value | Notes |
|---|---|---|
| Solid storage temperature | -20 °C or below | Desiccated and protected from light |
| Solution storage temperature | -80 °C as single-use aliquots | Avoid repeated freeze-thaw cycles |
| Purity assessment method | RP-HPLC, around 214 nm | Reported as main-peak area percent |
| Identity confirmation method | ESI-MS or MALDI-TOF | Measured mass compared with calculated mass |
| Common synonyms | ACTH(4-10) analog; Met-Glu-His-Phe-Pro-Gly-Pro | Also written as Semaxum in some sources |
== Etymology and pronunciation == The word synovium is related to the word synovia in its sense meaning "synovial fluid". The latter was coined by Paracelsus. More information is given at Synovial fluid § Etymology and pronunciation.
CH3CO2H + H2O ⇌ CH3CO−2 + H3O+ a proton may hop from one molecule of acetic acid onto a water molecule and then onto an acetate anion to form another molecule of acetic acid and leaving the number of acetic acid molecules unchanged. This is an example of dynamic equilibrium. Equilibria, like the rest of thermodynamics, are statistical phenomena, averages of microscopic behavior. Le Châtelier's principle (1884) predicts the behavior of an equilibrium system when changes to its reaction conditions occur. If a dynamic equilibrium is disturbed by changing the conditions, the position of equilibrium moves to partially reverse the change. For example, adding more S (to the chemical reaction above) from the outside will cause an excess of products, and the system will try to counteract this by increasing the reverse reaction and pushing the equilibrium point backward (though the equilibrium constant will stay the same). If mineral acid is added to the acetic acid mixture, increasing the concentration of hydronium ion, the amount of dissociation must decrease as the reaction is driven to the left in accordance with this principle. This can also be deduced from the equilibrium constant expression for the reaction:
Their erect posture enabled early dinosaurs to breathe easily while moving, which likely permitted stamina and activity levels that surpassed those of "sprawling" reptiles. Erect limbs probably also helped support the evolution of large size by reducing bending stresses on limbs. Some non-dinosaurian archosaurs, including rauisuchians, also had erect limbs but achieved this by a "pillar-erect" configuration of the hip joint, where instead of having a projection from the femur insert on a socket on the hip, the upper pelvic bone was rotated to form an overhanging shelf.
Sources: en.wikipedia.org
Newsom was sworn in on January 7, 2019. Several recall attempts were launched against Newsom early in his tenure but failed to gain much traction. On February 21, 2020, a recall petition was introduced by Orrin Heatlie, a deputy sheriff in Yolo County. The petition mentioned Newsom's sanctuary state policy and said laws he endorsed favored "foreign nationals, in our country illegally"; said that California had high homelessness, high taxes, and low quality of life; and described other grievances. The California secretary of state approved it for circulation on June 10, 2020. Forcing the gubernatorial recall election required a total of 1,495,709 verified signatures. By August 2020, 55,000 signatures were submitted and verified by the secretary of state, and 890 new valid signatures were submitted by October 2020. The petition was initially given a signature deadline of November 17, 2020, but it was extended to March 17, 2021, after Judge James P. Arguelles ruled that petitioners could have more time because of the pandemic. Newsom's attendance at a party at The French Laundry in November 2020, despite his public health measures; voter anger over lockdowns, job losses, school and business closures; and a $31 billion fraud scandal at the state unemployment agency were credited for the recall's growing support.
== Clinical significance == Cavin-2/SDPR is shown to act as a metastasis suppressor by xenograft studies utilizing breast cancer cell lines. Cavin-2 may elicit its metastasis suppressor function by directly interacting with ERK and limiting its pro-survival role. Moreover, it is suggested that cavin-2 is silenced during breast cancer progression by promoter DNA methylation. Metastasis suppressor role of cavin-2 may go beyond breast cancer since tumor samples from bladder, colorectal, lung, pancreatic, and ovarian cancers as well as sarcomas also exhibited loss of cavin-2 expression.
Xylazine is a structural analog of clonidine and an α2-adrenergic receptor agonist, sold under many trade names worldwide, most notably the Bayer brand name Rompun, as well as Anased, Sedazine and Chanazine. Xylazine is a common veterinary drug used for sedation, anesthesia, muscle relaxation, and analgesia in animals such as horses, cattle, and other mammals. In veterinary anesthesia, it is often used in combination with ketamine. Veterinarians also use xylazine as an emetic, especially in cats. Drug interactions vary with different animals. Xylazine was first investigated for human use in the 1960s in West Germany for antihypertensive effects before being discontinued and marketed as a veterinary sedative. Xylazine's mechanism of action was discovered in 1981, which led to the creation of other α2-adrenergic receptor agonists such as medetomidine and dexmedetomidine. Xylazine has become a commonly abused street drug in the United States where it is known by the street name "tranq", particularly in the territory of Puerto Rico. The drug is used as a cutting agent for heroin and fentanyl.
Chair of Trustees, Molly Rose Foundation. For services to Child Safety Online. Martin Henry Charles Russell, DL. For services to the community in the London Borough of Barnet. Rosemary Priscilla Irene Russell. Art and Design and Technology Technician, The Ursuline Academy Ilford. For services to Education and to Diversity in STEM. Elizabeth Joan Ryan. Lately Volunteer, Luton, South Bedfordshire and Harpenden Samaritans. For services to Suicide Prevention. Sadia Sadiq. Manager, Community Care and Wellbeing Services. For services to Minority Ethnic Communities in Wales. Lorraine Sanda. Strategic Director of People, Clackmannanshire Council. For services to Children and Families. Carolene Euleata Sargeant (Carolene Hinds). Independent Performing Arts Professional. For services to Dance. Professor William Peter Saunders. Chief Creative Officer, StoryFutures at Royal Holloway University. For services to the Creative Industries. Alison Melanie Savage. Officer Commanding, The Services Cotswold Centre. For services to Military Families. Jacqueline Savage. Volunteer. For services to Social Care. Majida Aly Sayam. Founder and Director, Jannaty Women's Social Society. For charitable services to Ethnic Minority Women. Kimberley Louise Scott. Lately Assistant Director of Education, Education Authority. For services to Education. Jacqueline Scrivens (Jacqueline Forester). Proprietor, The Woodshed Forest School Nursery. For services to Early Years Child-Lead Learning. Josephine Patricia Segal. Co-Founder, Spread a Smile.
Sources: en.wikipedia.org
=== Neonatal abstinence === Buprenorphine has been used in the treatment of the neonatal abstinence syndrome, a condition in which newborns exposed to opioids during pregnancy demonstrate signs of withdrawal. In the United States, use currently is limited to infants enrolled in a clinical trial conducted under an FDA-approved investigational new drug (IND) application. Preliminary research suggests that buprenorphine is associated with shorter time in hospital for neonates, compared to methadone. An ethanolic formulation used in neonates is stable at room temperature for at least 30 days.
== History == Carfilzomib is derived from epoxomicin, a natural product that was shown by the laboratory of Craig Crews at Yale University to inhibit the proteasome. The Crews laboratory subsequently invented a more specific derivative of epoxomicin named YU101, which was licensed to Proteolix, Inc. Scientists at Proteolix invented a new, distinct compound that had potential use as a drug in humans, known as carfilzomib. Proteolix advanced carfilzomib to multiple phase I and II clinical trials, including a pivotal phase 2 clinical trial designed to seek accelerated approval. Clinical trials for carfilzomib continue under Onyx Pharmaceuticals, which acquired Proteolix in 2009. In January 2011, the FDA granted carfilzomib fast-track status, allowing Onyx to initiate a rolling submission of its new drug application for carfilzomib. In December 2011, the FDA granted Onyx standard review designation, for its new drug application submission based on the 003-A1 study, an open-label, single-arm phase IIb trial. The trial evaluated 266 heavily-pretreated patients with relapsed and refractory multiple myeloma who had received at least two prior therapies, including bortezomib and either thalidomide or lenalidomide. Initial approval was based on response rate. Data demonstrating an overall survival benefit was demonstrated in the ENDEAVOR trial and approved by the FDA.
=== Eligibility for different stages of treatment === While a mental health assessment is recommended as standard practice by the WPATH Standards of Care (SoC), psychotherapy is not an absolute requirement but is highly recommended. Hormone replacement therapy is to be initiated from a qualified health professional. The general requirements, according to the WPATH standards, include:
The efficacy of quinacrine was assessed in a rigorous clinical trial in the UK and the results were published in Lancet Neurology, and concluded that quinacrine had no measurable effect on the clinical course of CJD. Astemizole, a medication approved for human use, has been found to have anti-prion activity and may lead to a treatment for Creutzfeldt–Jakob disease. A monoclonal antibody (code name PRN100) targeting the prion protein (PrP) was given to six people with Creutzfeldt–Jakob disease in an early-stage clinical trial conducted from 2018 to 2022. The treatment appeared to be well-tolerated and was able to access the brain, where it might have helped to clear PrPC. While the treated patients still showed progressive neurological decline, and while none of them survived longer than expected from the normal course of the disease, the scientists at University College London who conducted the study see these early-stage results as encouraging and suggest conducting a larger study, ideally at the earliest possible intervention.
Naloxegol (INN; PEGylated naloxol; trade names Movantik and Moventig) is a peripherally acting μ-opioid receptor antagonist developed by AstraZeneca, licensed from Nektar Therapeutics, for the treatment of opioid-induced constipation. It was approved in 2014 in adult patients with chronic, non-cancer pain. Doses of 25 mg were found safe and well tolerated for 52 weeks. When given concomitantly with opioid analgesics, naloxegol reduced constipation-related side effects, while maintaining comparable levels of analgesia. The most common side effects are abdominal pain, diarrhea, nausea, flatulence, vomiting, and headache. Naloxegol was previously a Schedule II drug in the United States because of its chemical similarity to noroxymorphone. It was officially decontrolled in January 2015. It was reclassified as a prescription drug after the FDA and DEA concluded that the impermeability of the blood–brain barrier to this compound made it non-habit-forming, and so without the potential for abuse.
Sources: en.wikipedia.org
Each freeze-thaw cycle can degrade a fraction of the peptide and promote aggregation. Dividing a stock solution into single-use volumes removes repeated cycling as a variable. It also limits the time a thawed solution spends at room temperature.
A high main-peak percentage says little about identity, counter-ion content, or residual solvents. It also does not distinguish an isomer or a closely eluting analog. Mass confirmation and the accompanying documentation cover those gaps.
Salt form changes mass, solubility, and hygroscopicity, and acetate and trifluoroacetate salts behave differently in solution. Storage guidance still centers on -20 °C for powder and lower temperatures for solutions. The certificate should state which salt is present.
Reversed-phase high-performance liquid chromatography is the standard method, with detection in the ultraviolet range. Peak area percentage yields a purity figure for the main component. Mass spectrometry is normally run alongside to confirm molecular identity.